Drugs / PF-07261271
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05536440 | Oct 2022 → Feb 2024 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07261271 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05536440 ↗ |
| Route | Intravenous | “single intravenous and multiple subcutaneous and intravenous doses of PF-07261271 in healthy participants” NCT05536440 ↗ |
| Route | Subcutaneous | “single intravenous and multiple subcutaneous and intravenous doses of PF-07261271 in healthy participants” NCT05536440 ↗ |